CohBar Inc
Change company Symbol lookup
Select an option...
CWBR CohBar Inc
CBDS Cannabis Sativa Inc
DPLS Darkpulse Inc
CAT Caterpillar Inc
AMT American Tower Corp
SUI Sun Communities Inc
XTNT Xtant Medical Holdings Inc
BAC Bank of America Corp
VST Vistra Corp
AVOA Avoca LLC
Go

Health Care : Biotechnology | Small Cap Growth
Company profile

CohBar, Inc. (CohBar), is a clinical stage biotechnology company. The Company is focused on the research and development of mitochondria-based therapeutics (MBTs) for the treatment of chronic and age-related diseases. The Company has discovered more than 100 mitochondrial-derived peptides and is focused on the development of these peptides into therapeutics that offer the potential to address a broad range of diseases, including nonalcoholic steatohepatitis (NASH), obesity, cancer, fibrotic diseases including idiopathic pulmonary fibrosis (IPF), type 2 diabetes (T2D), cardiovascular and neurodegenerative diseases. The Company’s lead compound, CB4211, is in the phase 1b stage of a phase 1a/1b clinical trial for NASH and obesity. In addition, CohBar has four preclinical programs that include MBT5 Analogs (CXCR4 Antagonists) for Cancer and Other Disease Indicatio, MBT2 Analogs for Fibrotic Diseases, MBT3 Analog for Cancer Immunotherapy and CB5064 Analogs for Type 2 Diabetes.

Closing Price
$1.20
Day's Change
0.10 (9.09%)
Bid
--
Ask
--
B/A Size
--
Day's High
1.22
Day's Low
1.11
Volume
(Light)
Volume:
228,022

10-day average volume:
346,242
228,022

Display:

Providers:

UpdateCancel
6 providers
May 03, 2021
CohBar to Announce 2021 First Quarter Financial Results and Provide Business Update on May 17, 2021

CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company developing mitochondria based therapeutics to treat chronic diseases and extend healthy lifespan, announced today that the company will release its first quarter 2021 financial...(Globe Newswire)

April 27, 2021
CohBar Appoints Joseph J. Sarret, M.D., J.D. as Chief Executive Officer and Director

CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company developing mitochondria based therapeutics to treat chronic diseases and extend healthy lifespan, today announced the appointment of Joseph J. Sarret, M.D., J.D. as Chief Executive...(Globe Newswire)

April 21, 2021
CohBar Completes Last Subject Visit in the Phase 1b Clinical Trial for CB4211 Under Development for NASH and Obesity

CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company developing mitochondria based therapeutics to treat chronic diseases and extend healthy lifespan, today announced that the last subject has completed their final visit in the Phase...(Globe Newswire)

April 14, 2021
CohBar to Present at the Mitochondria-Targeted Drug Development Summit

CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company developing mitochondria based therapeutics to treat chronic diseases and extend healthy lifespan, announced today that its Chief Executive Officer Steven Engle will present at the...(Globe Newswire)

March 30, 2021
CohBar Reports Fourth Quarter 2020 Financial Results and Provides Business Update

CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company developing mitochondria based therapeutics to treat chronic diseases and extend healthy lifespan, today reported its financial results for the fourth quarter ended December 31...(Globe Newswire)

CohBar, Inc. to Host Earnings Call

NEW YORK, NY / ACCESSWIRE / March 30, 2021 / CohBar, Inc. (NASDAQ:CWBR) will be discussing their earnings results in their 2020 Fourth Quarter Earnings call to be held on March 30, 2021 at 5:00 PM Eastern Time. (Accesswire)

March 29, 2021
CohBar Completes Enrollment in the Phase 1b Clinical Trial for CB4211 Under Development for NASH and Obesity

CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company developing mitochondria based therapeutics to treat chronic diseases and extend healthy lifespan, today announced the completion of enrollment in the Phase 1b stage of the CB4211...(Globe Newswire)

March 16, 2021
CohBar to Announce 2020 Fourth Quarter Financial Results and Provide Business Update on March 30, 2021

CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company developing mitochondria based therapeutics to treat chronic diseases and extend healthy lifespan, announced today that the company will release its fourth quarter 2020 financial...(Globe Newswire)

CohBar Nominates CB5138 Analog as Lead Clinical Candidate for Idiopathic Pulmonary Fibrosis and other Fibrotic Diseases

CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company developing mitochondria based therapeutics to treat chronic diseases and extend healthy lifespan, today announced the selection of CB5138-3 as its lead candidate for advancement...(Globe Newswire)

March 12, 2021
CohBar to Participate in M Vest LLC and Maxim Group LLC Inaugural Emerging Growth Virtual Conference

CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company developing mitochondria based therapeutics to treat chronic diseases and extend healthy lifespan, announced today that CEO Steven Engle will participate in a fireside chat with...(Globe Newswire)

March 02, 2021
CohBar to Present at the 33rd Annual ROTH Conference

CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company developing mitochondria based therapeutics to treat chronic diseases and extend healthy lifespan, announced today that its Chief Executive Officer, Steven Engle, will participate...(Globe Newswire)

February 25, 2021
CohBar to Present at the H.C. Wainwright Global Life Sciences Conference

CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company developing mitochondria based therapeutics to treat chronic diseases and extend healthy lifespan, announced today that its Chief Executive Officer, Steven Engle, will present a...(Globe Newswire)

Earnings Calendar and Events Data provided by |Terms of Use| © 2021 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

"Hot" indicates urgent and noteworthy news stories as determined by providers Dow Jones or Benzinga. TD Ameritrade does not select or recommend "hot" stories.

Information and news provided by ,, , Computrade Systems, Inc., , and

Copyright © 2021. All rights reserved.